Clinical evaluation of T-2588 on respiratory tract infections

T-2588 is a new cephem antibiotic with a broad spectrum of antibacterial activity. We performed the following clinical evaluation of T-2588 on 18 patients with respiratory tract infections including 10 cases of pneumonia, 5 of exacerbation of bronchiectasis, 2 of acute bronchitis and one of exacerbation of chronic bronchitis. Clinical responses were excellent in 8 cases, good in 9 and poor in one. T-2588 also showed the excellent in vitro antimicrobacterial activity against the clinical isolates including 5 strains of Haemophilusk influenzae, 3 strains of Streptococcus pneumoniae, each one strain of Klebsiella pneumoniae and Providencia rettgeri. The side effect was found in one case ; hypertransaminasemia. It was mild and disappeared spontaneously. From the above results, it was considered that T-2588 would be expected to be useful for the treatment of patients with respiratory tract infections.